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Preliminary results of an escalating dose phase I /II clinical trial of 
the anti EGFR monoclonal antibody nimotuzumab in combination 
with external radiotherapy in patients diagnosed with stage IIB, III 
or IV NSCLC unsuitable for radical therapy
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Background: The epidermal growth factor receptor (EGFR) has 
been implicated in pre-clinical models of non small cell lung cancer 
(NSCLC) as contributing to angiogenesis, metastasis, and resistance 
to radiation and chemotherapy, while its over expression is associ-
ated with poorer outcome. Nimotuzumab is a humanized monoclonal 
antibody (mAb) directed against the extracellular domain of human 
EGFR1 that does not exhibit the typical skin and GI toxicity seen with 
other agents in this class. Nimotuzumab administered concurrently with 
radiotherapy is a well-tolerated combination that may enhance radio-
curability of unresectable head and neck neoplasms. Here we outline 
the preliminary results of a phase I/II trial of this agent given concur-
rently with palliative radiation in patients with NSCLC.
Methodology: Eligible patients (age >18 years; histologically or cyto-
logically conﬁrmed Stage IIB, III or IV NSCLC; unsuitable for radical 
radiation or chemo-radiation; measurable disease within the planned 
radiation ﬁeld) received nimotuzumab as a 30 minute IV infusion 
weekly on weeks 1 - 8 starting on day 1, 2 to 6 hrs after radiation (30 
Gy 10 fractions, Monday to Friday). If response or disease stability was 
observed, nimotuzumab was continued every other week starting from 
week 10 until progression or toxicity.
Results: 6 patients (age 60 - 81; median age 76) have been enrolled in 
the 1st cohort (100mg) of the study. Stages at diagnosis were IIIA - 2; 
IIIB - 3; IV - 1. To date 2 PR, two SD, and one DP have been observed. 
Median overall survival of the group is 26 weeks. Two patients have 
died of progressive disease and two patients have withdrawn from the 
study. Two SAE’s have been reported, but neither one has been caus-
ally attributable to Nimotuzumab. There has been a notable absence of 
grade III IV rash or diarrhea in this cohort. 
Patient # Age
NSCLC 
Stage
Prior 
Therapy
Best 
Response
Survival from  
1st dose (Wks)
Current 
Status
1 76 IIIA None PR 51w+ Withdrawn
2 81 IIIB None SD 39+ Ongoing
3 * 74 IIIA Chloram-bucil NA NA Withdrawn
4 76 IIIB None SD 24 Died 
5 67 IIIB None PR 14 Died 
6 60 IV None DP 17+ Ongoing
*Not eligble for the study because of concurrent CLL
Conclusion: Nimotuzumab administered concurrently with radiation is 
well tolerated at this dose in NSCLC patients. Although it speciﬁcally 
targets the EGF receptor, the absence of rash and diarrhea makes it 
therapeutically attractive. Four patients have now been enrolled in the 
second cohort (200mg) and the updated results will be presented at the 
congress.
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Sodiumselenite in the treatment of lung cancer
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Option: Resistance to chemotherapy is a major obstacle to improved 
survival in NSCLC and SCLC. In vitro, selenite in fairly moderate con-
centration kills most lung cancer cell lines. We have started a clinical 
study on selenite to patients with chemotherapy resistant lung cancer.
Background. In vitro studies of lung cancer, mesotelioma and leuce-
mia cell lines have demonstrated that sodiumselenite in doses above 5 
micromol/L induces apoptosis in most cell lines. It is accomplished in 
a different manner compared to clinically used cytotoxic drugs, since 
there seems to be especially the drug resistant cell lines that are sensi-
tive to selenite. An enzyme thioredoxin reductase seems to be involved 
in the process. High doses of this enzyme protects against the oxida-
tive stress produced by cytotoxic drugs but not to selenite. An additive 
effect of selenite and chemotherapy is also seen. One further ﬁnding 
makes sodium selenite interesting in this context. During the seven-
ties sodiumselenite with Se75 was used as a tumor seeking tracer for 
scintigraphy, making it probable that a favourable Se gradient might be 
found clinically.
Patients and methods: The maximal tolerable dose (MTD) of sodium 
selenite is not known. Therefore we have started with an ordinary phase 
I study to deﬁne MTD. Selenium is given in daily doses during a ﬁve 
week period. After that a response evaluation is performed and patients 
not acquiring a complete response are two weeks after the selenite stop 
given chemotherapy. When MTD is found we will proceed with an 
ordinary phase II study with response as the primary endpoint. Serum 
and tumour samples will be taken both in the phase I and II studies to 
study dose-effect relationship and to seek predictive factors among 
others with microarray expression in untreated and treated tumour cells.
Results: The ﬁrst patient in the phase I study has just gone through the 
selenite treatment without side effects. The next two on the ﬁrst treat-
ment level are just going to start. Further results from the phase I study 
will be presented at the meeting.
Conclusion: If selenite could be given in sufﬁcient doses to kill tumor 
cells with acceptable side effects it would probably be a cheap and use-
ful complement to cytotoxic drugs. 
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Activity of the protein kinase C beta inhibitor enzastaurin in lung 
cancer cell lines
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Background: Combining existing lung cancer therapies with novel 
agents that interfere with major signaling pathways is a promising ap-
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proach. Targeting protein kinase Cß (PKCß) may serve as an attractive 
candidate because activation of PKCß has been implicated in tumor 
proliferation, survival, invasion, and angiogenesis in model systems. 
Enzastaurin is a selective PKCß inhibitor. There is evidence for its ef-
ﬁcacy in both preclinical and clinical trials. The objective of this study 
was to assess the effect of enzastaurin on proliferation and phosphopro-
tein signaling in lung cancer. 
Methods: Four non small cell lung cancer (non-SCLC) cell lines 
(H125, H322, H23, A549) and four SCLC cell lines (H69, SW210.5, 
DMS-79, H211)] were tested. Cells were exposed to different doses of 
enzastaurin for 4 days, and the anti-proliferation effect was assessed 
with the CellTiter-Glo Luminescent Cell Viability Assay. The efﬁciency 
of enzastaurin in suppressing intracellular phosphoprotein signaling 
in these cells was tested at 1µmol/L concentrations at difference time 
points (0.5, 1, 2, 4 hours). PKCβII and phospho-PKCβII(ser660), 
GSK3β and phospho-GSK3β(ser9), ribosomal protein S6 and phospho- 
ribosomal protein S6(ser240/244) were measured by western blotting. 
Results: Enzastaurin suppressed cell proliferation of all NSCLC 
and SCLC cell lines in the low micromolar range (0.1, 1, 5µM). 
Western blot analysis of these cells showed that phosphorylation of 
PKCβII(ser660), GSK3β(ser9) and ribosomal protein S6(ser240/244) 
were suppressed in a time-dependent manner after enzastaurin treat-
ment.
Conclusions: These data indicate that enzastaurin has a direct anti-
cancer effect through suppression of proliferation, and they suggest 
that this effect is mediated by inhibition of intracellular phosphoprotein 
signaling.
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Background: RAD001C (everolimus) is an oral inhibitor of mamma-
lian target of rapamycin (mTOR) with anti-tumor activity. As single-
agent and in combination with other anticancer agents, RAD001C 
showed efﬁcacy in in vitro and in vivo NSCLC models. RAD001C is 
currently being investigated in clinical trials as an anticancer agent in 
patients with advanced lung cancer. In a phase I study, 4 disease stabili-
zations (SD) and 1 partial response (PR), as per RECIST, were reported 
from 14 NSCLC patients treated with RAD001C monotherapy. Further 
phase Ib studies have been designed to investigate the feasibility of dif-
ferent regimens combining RAD001 doses and schedules with selected 
standard chemotherapeutic agents in patients with advanced non-small 
cell lung cancer (NSCLC) and small cell lung cancer (SCLC). A novel 
statistical design was tailored to optimize the regimen selection in this 
combination phase Ib setting.
Methods: Three phase I, open-label, multi-center studies of RAD001 
with standard chemotherapy in patients with advanced NSCLC or 
SCLC are designed as an adaptive Bayesian dose-escalation scheme. 
This is based on a Time-to-DLT (Dose Limiting Toxicity) model esti-
mating the risk that patients experience a DLT within their ﬁrst cycle 
of treatment (as primary endpoint) or at any other time-point during the 
study. This novel statistical design improves on the traditional phase 
I designs. The adaptive nature of the Bayesian methodology allows 
the DLT rate to be re-evaluated at any time during the study, allowing 
quicker intervention following toxicity events, without the constraint of 
ﬁxed-size cohorts of patients. Decision-making takes into account all 
available information from all patients in the study thanks to the time-
to-event model. All toxicities occurring at any time during treatment 
are incorporated. In this phase Ib combination setting, the knowledge 
already available on the safety proﬁle of the individual agents allows to 
make full use of the Bayesian methodology to identify the optimal dose 
(in terms of toxicity proﬁle) for future studies. DLT rates are provided 
with model-based conﬁdence intervals. The way the design operates 
has been investigated under a variety of toxicity scenarios. In particu-
lar, the risk to choose too high (too toxic) or too low a dose has been 
calculated and discussed versus traditional designs.
Results: Studies are ongoing. Results will be provided as available 
with a discussion of advantages and disadvantages of the novel phase I 
study design.
Conclusions: This adaptive phase Ib study design may be considered 
as a better decision-making tool which can exploit all safety informa-
tion available and ensure higher conﬁdence in the regimen selected for 
later phase clinical studies.
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cisplatin in lewis lung cancer and human a 549 lung cancer models
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Purpose: To fully explore the clinical possibility of honokiol, we 
encapsulated honokiol with long circulating liposome to improve its 
solubility and prolong its circulation time in body. The potential to in-
crease the antitumor effect of liposomal honokiol by combination with 
cisplatin and possible mechanism have been investigated in in vitro and 
in vivo. 
Experimental Design: Honokiol was encapsulated with long circulat-
ing modiﬁed liposomes. The pharmacokinetic study and biodistribution 
of liposomal honokiol in tumor-bearing mice was detected by high 
performance liquid chromatography. Inhibition of cell proliferation and 
induction of apoptosis by liposomal honokiol were tested in vitro. In 
in vivo study, LL/2 tumor model and human A549 tumor models were 
established in C57BL/6N mice and athymic nude mice, respectively. 
Mice were treated with PBS group, liposomal honokiol, free lipo-
some, cisplatin, and liposomal honokiol plus cisplatin. Tumor volume 
and survival time were observed and the mechanisms underlying the 
anti-tumor effect was investigated by detecting the microvessel density, 
apoptosis in tumor tissue.
Results: Liposomal honokiol has shown remarkable improvement 
of water solubility and could be dissolved in PBS for i.p injection. 
